Bilateral intravitreal injection of antivascular endothelial growth factor therapy

Vinit B Mahajan; Kori A Elkins; Stephen R Russell; H Culver Boldt; Karen M Gehrs; Thomas A Weingeist; Edwin M Stone; Michael D Abràmoff; Dawei Liu; James C Folk

doi:10.1097/IAE.0b013e3181ed8c80

Back

Bilateral intravitreal injection of antivascular endothelial growth factor therapy

Journal article

Peer reviewed

Bilateral intravitreal injection of antivascular endothelial growth factor therapy

Vinit B Mahajan, Kori A Elkins, Stephen R Russell, H Culver Boldt, Karen M Gehrs, Thomas A Weingeist, Edwin M Stone, Michael D Abràmoff, Dawei Liu and James C Folk

Retina (Philadelphia, Pa.), Vol.31(1), pp.31-35

01/2011

DOI: 10.1097/IAE.0b013e3181ed8c80

PMID: 21187731

View Online

Abstract

The purpose of this study was to review adverse events and patient preference after bilateral intravitreal injection of antibodies to vascular endothelial growth factor. A retrospective case-control study. Patients with exudative age-related macular degeneration who received intravitreal antivascular endothelial growth factor agent injections in both eyes (bilateral group) on the same day over a 23-month period were compared with patients who received injections in only 1 eye. The occurrence of endophthalmitis, cerebrovascular accident, myocardial infarction, death, patient discomfort, and patient preference was compared between the two groups. One hundred and two patients received an average of 4.43 bilateral injections (range 1-13). A case-control group of 102 patients received an average of 10.2 unilateral injections, (range 2-28). Bevacizumab was injected 45.5%, ranibizumab 45.5%, and a combination of bevacizumab and ranibizumab 9% of the time for bilateral injections. Bevacizumab was used 50.3% and ranubizumab 49.7% of the time in unilateral injections. The follow-up of both groups averaged 18.4 months (range 4.7-36.5 months). There were no cases of endophthalmitis or cerebrovascular accident in either group. There was a single case of myocardial infarction in each group. There were two deaths in the bilateral group and three deaths in the unilateral group. More than 90% strongly preferred bilateral injections to unilateral injections. Bilateral injections of antivascular endothelial growth factor agents on the same day did not increase the rate of adverse events and was preferred by the majority of patients.

Myocardial Infarction - chemically induced

Myocardial Infarction - epidemiology

Follow-Up Studies

Humans

Middle Aged

Antibodies, Monoclonal - adverse effects

Male

Vascular Endothelial Growth Factor A - antagonists & inhibitors

Case-Control Studies

Macular Degeneration - drug therapy

Bevacizumab

Incidence

Antibodies, Monoclonal, Humanized

Ranibizumab

Aged, 80 and over

Vitreous Body

Female

Retrospective Studies

Drug Administration Schedule

Patient Preference

Macular Degeneration - mortality

Antibodies, Monoclonal - administration & dosage

Aged

Drug Combinations

Injections, Intraocular

Details

Title: Subtitle: Bilateral intravitreal injection of antivascular endothelial growth factor therapy
Creators: Vinit B Mahajan - Department of Ophthalmology and Visual Sciences, The University of Iowa Hospitals & Clinics, Iowa City, IA, USA. mahajanlab@gmail.com
Kori A Elkins
Stephen R Russell
H Culver Boldt
Karen M Gehrs
Thomas A Weingeist
Edwin M Stone
Michael D Abràmoff
Dawei Liu
James C Folk
Resource Type: Journal article
Publication Details: Retina (Philadelphia, Pa.), Vol.31(1), pp.31-35
DOI: 10.1097/IAE.0b013e3181ed8c80
PMID: 21187731
NLM abbreviation: Retina
ISSN: 0275-004X
eISSN: 1539-2864
Publisher: United States
Language: English
Date published: 01/2011
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Electrical and Computer Engineering; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Ophthalmology and Visual Sciences
Record Identifier: 9983806280802771

Metrics

27 Record Views

30 Times Cited - Web of Science

See more details